Results of INTERLACE, a phase III multicentre randomized study is the first to "show a significant survival advantage with the addition of induction chemotherapy before chemoradiotherapy in locally advanced cervical cancer." 5-year progression-free survival was significant: 72% in patients administered induction chemotherapy with chemoradiotherapy, compared to 64% receiving chemoradiotherapy alone.
To learn more about this study, click here.
Sources mentioned:
- McCormack M, Eminowicz G, Gallardo D, et al. on behalf of the INTERLACE investigators. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial. The Lancet 2024;404(10462):P1525-1525.
- Duska LR, Randall LM. Progress in the treatment paradigms for locally advanced cervical cancer. The Lancet 2024;404(10462):p1494-1496.
No comments:
Post a Comment